Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

HIV entry inhibitors in clinical development.

Bryan M O'Hara1, William C Olson

  • 1Progenics Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. bohara@progenics.com

Current Opinion in Pharmacology
|September 27, 2002
PubMed
Summary

New HIV-1 therapies are needed due to current treatment limitations. Entry inhibitors offer a promising new approach by targeting the virus

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat).

Blood·2026
Same author

CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo.

Science translational medicine·2025
Same author

Structural characterization of two γδ TCR/CD3 complexes.

Nature communications·2025
Same author

Structures of complete extracellular assemblies of type I and type II Oncostatin M receptor complexes.

Nature communications·2024
Same author

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies.

Cell reports. Medicine·2024
Same author

Structural insights into CXCR4 modulation and oligomerization.

Nature structural & molecular biology·2024

Area of Science:

  • Virology
  • Immunology
  • Drug Discovery

Background:

  • Current human immunodeficiency virus type 1 (HIV-1) therapies fail to eradicate the virus, leading to multidrug-resistant variants and toxicities.
  • Existing treatments target two key viral enzymes in intracellular replication, highlighting the need for novel therapeutic strategies.
  • HIV-1 infection requires a multistep entry process involving viral attachment, co-receptor interactions, and fusion.

Purpose of the Study:

  • To explore the potential of targeting the HIV-1 entry pathway for therapeutic intervention.
  • To review the development and promise of entry inhibitors as a new class of anti-HIV-1 agents.

Main Methods:

  • Review of existing literature on HIV-1 replication and entry mechanisms.
  • Analysis of clinical data for entry inhibitors targeting different stages of the viral entry cascade.

Main Results:

  • Clinical proof-of-principle has been established for inhibitors targeting each step of HIV-1 entry.
  • Entry inhibitors represent a viable therapeutic strategy distinct from current enzyme-targeting drugs.

Conclusions:

  • Targeting HIV-1 entry offers a promising avenue for developing new therapies.
  • Entry inhibitors provide a novel approach to combatting HIV-1 infection, addressing limitations of current treatments.

Related Experiment Videos